Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
43 participants
INTERVENTIONAL
2009-02-13
2014-10-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
NCT06325722
Factors Affecting Caloric Regulation in Human Feeding
NCT00108784
Neural and Metabolic Factors in Carbohydrate Reward
NCT06053294
Effects of a Ketogenic Diet on Body Weight and Cardiovascular Risk Factors
NCT00498394
Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes
NCT00108459
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives:
\- To determine the comparative effects of two controlled fat- or carbohydrate-restricted diets and an outpatient weight loss program on blood and brain chemical composition, weight loss (fat and lean body mass), and regional brain activity in lean and obese individuals.
Eligibility:
\- Healthy individuals between 18 and 45 years of age who are either lean (body mass index between 18.5 kg/m(2) and 25 kg/m(2)) or obese (body mass index above 30.0 kg/m(2), weight less than 350 pounds) and are right-handed.
Design:
* Lean participants: Participants will be screened with a medical history, physical examination, blood and urine tests, and weight maintenance observations (food diaries and physical activity monitors). For the scanning visit, participants will receive balanced meals from the National Institutes of Health to consume for 2 days before the visit. During the scanning visit, participants will continue to eat the weight maintenance diet, complete questionnaires, and have a series of imaging studies (including positron emission tomography and magnetic resonance imaging tests) to evaluate brain response to food and other stimuli.
* Obese participants: Participants will be screened with a medical history, physical examination, blood and urine tests, and weight maintenance observations (food diaries and physical activity monitors). During the first inpatient visit, obese participants will eat a weight-maintenance diet for 5 days to establish baseline measurements. After several days of eating a weight-maintenance diet, 20 obese adult volunteers (BMI above 30 kg/m2) will be admitted to the metabolic clinical research unit (MCRU) and, after 5 additional days of the baseline diet, their diets will be modified to result in either 85% reduction of the baseline dietary fat or a 60% reduction of the baseline dietary carbohydrate for the next 6 days. These diet modifications produce an equivalent caloric reduction. The primary outcome measurements will be changes of metabolism, brain reward circuitry and regional brain activity in response to food stimuli measured during the baseline and reduced calorie diet phases. Immediately following each controlled diet, we will measure 3 days of ad-libitum food intake using a computerized vending machine system. The subjects will return to the MCRU after a 2-10 week washout period to receive the opposite reduced calorie diet. Twenty control subjects with normal body weight (BMI between 18.5 - 25 kg/m2) will have measurements of brain reward circuitry and regional brain activity in response to food stimuli while on a balanced, weight-maintenance diet. Immediately following the second in-patient visit, all of the obese subjects will be assigned to a 12 week out-patient weight loss program with the goal of achieving at least 5% weight loss. We will investigate the relationship between short-term fat imbalances measured during the in-patient phases, and the body weight and fat changes during the weight loss program. We will evaluate the effects of weight loss on metabolism, brain reward circuitry, and regional brain activity in response to food stimuli. Finally, if the subjects are available for long-term follow-up, then we will investigate their metabolic phenotype, brain reward circuitry, and regional brain activity in response to food stimuli yearly over the subsequent 5 years following the weight loss intervention. This study will result in an improved understanding of the physiological mechanisms that sense and respond to negative energy balance acutely, after several weeks, and after several years, and may eventually lead to increased long-term success of obesity treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Obese RF then RC
Obese adult volunteers (BMI above 30 kg/m2) randomized to receive an 85% reduction of baseline dietary fat (RF) for 2 weeks. After a washout period of 2 weeks, they then received a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks
Reduced fat diet
RF (selective reduction of 85% of baseline fat calories per day)
Reduced carbohydrate diet
RC (selective reduction of 60% of baseline carbohydrate calories per day)
Drug: f-18 fallypride
Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
fMRI
Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
PET
Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
Obese RC then RF
Obese adult volunteers (BMI above 30 kg/m2) randomized to receive a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks. After a washout period of 2 weeks, they then received an 85% reduction of baseline dietary fat (RF) for 2 weeks.
Reduced fat diet
RF (selective reduction of 85% of baseline fat calories per day)
Reduced carbohydrate diet
RC (selective reduction of 60% of baseline carbohydrate calories per day)
Drug: f-18 fallypride
Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
fMRI
Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
PET
Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
Lean Control
Lean adult volunteers (BMI below 30kg/m2) placed on a weight-maintenance diet using a standard diet composition of 50% carbohydrate, 35% fat, and 15% protein on an out-patient basis
Drug: f-18 fallypride
Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
fMRI
Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
PET
Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Reduced fat diet
RF (selective reduction of 85% of baseline fat calories per day)
Reduced carbohydrate diet
RC (selective reduction of 60% of baseline carbohydrate calories per day)
Drug: f-18 fallypride
Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
fMRI
Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
PET
Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass less than 350 lbs. (max. weight dictated by table limit for functional magnetic resonance imaging (fMRI) scanner) when acquisition of large bore fMRI is complete, max. wt. limit will increase to 400 lbs.
* Weight stable (less than plus or minus 5 kg over past 6 months)
* Body mass index greater than or equal to 30.0 kg/m(2)
* Premenopausal (women only)
* Healthy, as determined by medical history and laboratory tests
* Able to complete daily bouts of walking at a moderate rate
* Written informed consent
* Age 18-45 years, male or female
* 18.5 kg/m(2) less than BMI less than 25.0 kg/m(2)
* Weight stable (less than plus or minus 5 kg over past 6 months)
* Premenopausal (women only)
* Healthy, as determined by medical history and laboratory tests
* Written informed consent
Exclusion Criteria
* BMI less than 30.0 kg/m(2)
* Evidence of metabolic or cardiovascular disease, or disease that may influence metabolism (e.g. cancer, diabetes, thyroid disease)
* Taking any prescription medication (except birth control) or other drug that may influence metabolism (e.g. diet/weight-loss medication)
* Hematocrit less than 34% (women only)
* Hematocrit less than 40% (men only)
* Pregnancy, lactation (women only)
* Allergy to lidocaine or ethanol
* Participating in a regular exercise program (greater than 2h/week of vigorous activity)
* Caffeine consumption greater than 150 mg/day (will be clamped at baseline intake during study)
* Regular use of alcohol (greater than 2 drinks per day), tobacco (smoking or chewing), amphetamines, cocaine, heroin, or marijuana over past 6 months
* Past or present history of eating disorder (including binge eating) or psychiatric disease
* Volunteers with strict dietary concerns (e.g. vegetarian or kosher diet, multiple food allergies)
* Are claustrophobic to a degree that they would feel uncomfortable in the MRI machine.
* Having any metal in their body (for example, pacemakers, metallic prostheses such as cochlear implants or heart valves, shrapnel fragments, etc.).
* Left-handedness
* Non-native English speakers
* Volunteers unwilling or unable to give informed consent
Control Subjects
* BMI less than 18.5 or greater than 25.0 kg/m(2)
* Evidence of metabolic or cardiovascular disease, or disease that may influence metabolism (e.g. cancer or diabetes)
* Taking any prescription medication (except birth control) or other drug that may influence metabolism (e.g. diet/weight-loss medication)
* Hyperlipidemia (fasting plasma triglyceride concentration greater than 150 mg/dl)
* Hematocrit less than 34% (women only)
* Hematocrit less than 40% (men only)
* Pregnancy, lactation (women only)
* Participating in a regular exercise program (greater than 2h/week of vigorous activity)
* Caffeine consumption greater than 150 mg/day
* Regular use of alcohol (greater than 2 drinks per day), tobacco (smoking or chewing), amphetamines, cocaine, heroin, or marijuana over the past 6 months
* Past or present history of eating disorder (including binge eating) or psychiatric disease
* Volunteers with strict dietary concerns (e.g vegetarian or kosher diet, multiple food allergies)
* Are claustrophobic to a degree that they would feel uncomfortable in the MRI machine.
* Having any metal in their body (for example, pacemakers, metallic prostheses such as cochlear implants or heart valves, shrapnel fragments, etc.).
* Left-handedness
* Non-native English speakers
* Volunteers unwilling or unable to give informed consent
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin Hall, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999 Oct 27;282(16):1523-9. doi: 10.1001/jama.282.16.1523.
Allison DB, Zannolli R, Narayan KM. The direct health care costs of obesity in the United States. Am J Public Health. 1999 Aug;89(8):1194-9. doi: 10.2105/ajph.89.8.1194.
Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003 May 22;348(21):2074-81. doi: 10.1056/NEJMoa022637.
Hall KD, Bemis T, Brychta R, Chen KY, Courville A, Crayner EJ, Goodwin S, Guo J, Howard L, Knuth ND, Miller BV 3rd, Prado CM, Siervo M, Skarulis MC, Walter M, Walter PJ, Yannai L. Calorie for Calorie, Dietary Fat Restriction Results in More Body Fat Loss than Carbohydrate Restriction in People with Obesity. Cell Metab. 2015 Sep 1;22(3):427-36. doi: 10.1016/j.cmet.2015.07.021. Epub 2015 Aug 13.
Guo J, Simmons WK, Herscovitch P, Martin A, Hall KD. Striatal dopamine D2-like receptor correlation patterns with human obesity and opportunistic eating behavior. Mol Psychiatry. 2014 Oct;19(10):1078-84. doi: 10.1038/mp.2014.102. Epub 2014 Sep 9.
Simmons WK, Rapuano KM, Ingeholm JE, Avery J, Kallman S, Hall KD, Martin A. The ventral pallidum and orbitofrontal cortex support food pleasantness inferences. Brain Struct Funct. 2014 Mar;219(2):473-83. doi: 10.1007/s00429-013-0511-0. Epub 2013 Feb 9.
Simmons WK, Rapuano KM, Kallman SJ, Ingeholm JE, Miller B, Gotts SJ, Avery JA, Hall KD, Martin A. Category-specific integration of homeostatic signals in caudal but not rostral human insula. Nat Neurosci. 2013 Nov;16(11):1551-2. doi: 10.1038/nn.3535. Epub 2013 Sep 29.
Darcey VL, Guo J, Courville AB, Gallagher I, Avery JA, Simmons WK, Ingeholm JE, Herscovitch P, Martin A, Hall KD. Dietary fat restriction affects brain reward regions in a randomized crossover trial. JCI Insight. 2023 Jun 22;8(12):e169759. doi: 10.1172/jci.insight.169759.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-DK-0081
Identifier Type: OTHER
Identifier Source: secondary_id
090081
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.